Labiotech.eu

Weekly Recap of the Hottest M&A and Partnerships in the Biotech World! 🔥🤝 Merger and acquisition: 🔀                                                                                 🇮🇹 Angelini Pharma to acquire 🇺🇸 Catalyst Pharmaceuticals, Inc. for $4.1 billion | Lead product acquired: Firdapse (amifampridine) for Lambert-Eaton myasthenic syndrome 🇩🇪 Bayer to acquire 🇺🇸 Perfuse Therapeutics for up to $2.45 billion | Lead asset acquired: small molecule endothelin receptor antagonist for glaucoma and diabetic retinopathy Partnering: 🤝 🇺🇸 Bristol Myers Squibb collaborates with 🇨🇳 Hengrui Pharma to advance portfolio of 13 programs in oncology, hematology and immunology | potential total deal value of up to approximately $15.2 billion 🇬🇧 GSK partners with 🇨🇳 SiranBio for siRNA oligonucleotide for metabolic and vascular disease | SiranBio to receive upfront fee and up to $1.005 billion in milestone payments 🇩🇪 Boehringer Ingelheim partners with 🇺🇸 Immunitas Therapeutics for preclinical antibody program for inflammatory and autoimmune diseases | Immunitas to receive upfront payment and is eligible to receive up to €407.5 million ($478 million) in milestone payments Subscribe to our newsletter for more partnering updates!  🔗 https://lnkd.in/dsgz62YY #deals #partnering #mergers #acquisitions #biotech

Did you know that a new therapy is nearing approval for stiff person syndrome? ➡️👍 🦵 Stiff person syndrome is a rare autoimmune condition that causes muscle stiffness and can result in painful muscle spasms that affect the mobility and quality of life of patients.  ❌ There is no cure for the condition yet, and people with stiff person syndrome are often given off-label drugs.  However, a CAR-T cell therapy targeting the syndrome is being developed by Kyverna Therapeutics and is poised to receive approval from the FDA.  If approved, it would be the first to treat stiff person syndrome and the first CAR-T therapy to treat autoimmune conditions. 🥇 💬 Labiotech was in conversation with Kyverna Therapeutics’ Naji GEHCHAN, MD, MSc, MBA about the potential milestone. Read our latest article to learn more! 👇  https://lnkd.in/dSvnwhnV  #autoimmunedisease #raredisease #biotech #immunotherapy #neurology #healthcareinnovation #lifesciences #drugdevelopment 

How do you strengthen cell therapy supply chain from the get-go? 🧬 🚛 🎙️ On the latest episode of the Beyond Biotech Podcast, Labiotech’s Dylan Kissane sits down with Cryoport Systems’ Dominic Clarke, who has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. 🚀 They discuss how early decisions in cell therapy end up shaping or complicating everything that comes later, why teams switch to cryopreservation late, and what actually works to boost production. ⚡ 🎧 Tune in to the latest episode now! 👇  https://lnkd.in/dKweCDcw   #BeyondBiotechPodcast #celltherapy #biotech #supplychain #cryopreservation #advancedtherapies #lifesciences  

💰 Biotech's Top Investments This Week! 🚀 🇬🇧 Isomorphic Labs | $2.1 billion series B | AI drug design   🇺🇸 Avalo Therapeutics | $375 million public offering | IL-1β based treatments | lead asset for hidradenitis suppurativa 🇺🇸 Odyssey Therapeutics | $304 million IPO + private placement | autoimmune and inflammatory disease therapies | lead asset for ulcerative colitis 🇺🇸 Artiva Biotherapeutics | $300 million underwritten offering | cell therapies | lead asset for rheumatoid arthritis 🇬🇧 CellCentric | $220 million series D | oral p300/CBP inhibitor | phase 2 in multiple myeloma Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

Why is annotation still one of the most challenging steps in single-cell analysis? 💡 As datasets grow, the challenge is no longer generating data, but interpreting it with enough resolution to support decisions. Broad cell labels are often not enough: what matters is identifying functional states and relevant subpopulations. 🔎  AI is being used to add an interpretation layer, helping researchers structure this step and make results more consistent and traceable. 🤖 Nygen looks at how this approach could help close the gap between data and insight. ⬇️  https://lnkd.in/dkYHA2FJ  #singlecell #genomics #bioinformatics #AIinbiology #artificialintelligence #machinelearning #drugdiscovery #lifesciences #biotech

April 2026: Which companies bagged the biggest funding rounds of the month?

What do investors now look for in an AI biotech? 🤖 The biotech industry’s enthusiasm for artificial intelligence (AI) has not disappeared, but the conversation around the technology is becoming more grounded than it was during the first major wave of AI-focused biotech funding.💸 Sharon Gour Arie, chief operating officer (COO) at AION Labs, compares the evolution of the field to the Gartner Hype Cycle, where early excitement around a technology eventually gives way to a more pragmatic phase focused on tangible applications and productivity.  So what do investors such as Sergey Jakimov and Artem A. Trotsyuk from LongeVC look for in AI companies? 👇  https://lnkd.in/d7tunqpM  #AI #biotech #AIBiotech #artificialintelligence #drugdiscovery #biotechinnovation #healthtech  #innovation 

What does the TIL therapies landscape look like? 🔍 Tumor-infiltrating lymphocytes or TIL therapies are an emerging class of drugs designed to address solid tumors. 🎯 ✅ The first TIL therapy, Iovance Biotherapeutics, Inc.’ Amtagvi, was approved by the FDA two years ago for melanoma. Now, the field is growing with biotechs like Obsidian Therapeutics, KSQ Therapeutics, Inc., and CuraCell making progress. 🚀   💬 Labiotech has been in conversation with CTMC’s Chantale Bernatchez and CuraCell’s Jonas Båtelson to discuss the TIL therapeutics space.  Read our latest article to learn more! 👇  https://lnkd.in/dBK_93v8 #TILTherapy #cancerresearch #immunotherapy #oncology #biotech #precisionmedicine

Over the past few years, biotech layoffs have become an unavoidable reality across the biotech industry. Companies both large and small have had to reduce headcount, pause programs, and restructure operations in response to tightening capital markets, rising interest rates, clinical setbacks, and shifting investor expectations. 🧬📉 Sadly, for many professionals in biotech, layoffs are now almost an expected part of the industry cycle. But while the human and operational consequences of layoffs are obvious, the long-term risk implications are often less visible – which is where biotech risk management becomes vital. ⚠️ Read our latest article by Willow Shah-Neville to find out more about how layoffs can increase risk and how companies can protect themselves from this! 👇   https://lnkd.in/dHbUTJRx     #biotech #biotechlayoffs #riskmanagement #lifesciences #operationalrisk     Justin Kozak Founder Shield Christopher Coe Kingsley Gate    

How do CGT programs avoid becoming constrained by the very workflows that helped them get started? 🧬❄️ Fresh leukapheresis-derived starting material remains the dominant model across many cell and gene therapy programs today. But as programs expand across more patients, sites, and manufacturing demands, workflows built around narrow time windows can become increasingly difficult to coordinate. Questions around variability, scheduling pressure, manufacturing capacity, and standardization are pushing more companies to rethink how starting material is handled as they move toward late-stage development and commercialization. With integrated cryopreservation, biostorage, and logistics capabilities,  Cryoport Systems is helping support CGT supply chains designed for greater flexibility and scalability. ⬇️  https://lnkd.in/dfeaNRsr #cellandgenetherapy #biotech #cryopreservation #advancedtherapies #biostorage #coldchain #supplychain